T Cells clinical trials

Explore recruiting t cells clinical trials.

Recruiting t cells studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

T Cells trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector Cell-Associated Neurotoxicity Syndrome : the VESICANS study

France

Therapeutic use (Phase IV) EU CTIS Study details

CARMOD - Golcadomide (BMS-986369) post-CAR T-cell in R/R Aggressive large B-cell lymphoma patients with high risk of relapse

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retroviral vector – A unicenter Phase I/II clinical trial [HD-CAR-1]

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

BiCAR Therapy - A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells therapy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED (GENETICALLY MODIFIED) THROUGH A LENTIVIRAL VECTOR TO EXPRESS A CHIMERIC RECEPTOR WITH ANTI-CD19 SPECIFICITY ASSOCIATED WITH CO-STIMULATORY SEQUENCES 4-1-BB AND CD3Ζ IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA.

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial (TRACE)

Belgium, Germany, Italy, France, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

T Cells trials by city

T Cells in Toronto T Cells in Vancouver T Cells in Montreal T Cells in Calgary T Cells in Edmonton T Cells in Ottawa T Cells in Winnipeg T Cells in Quebec City T Cells in Hamilton T Cells in Kitchener T Cells in London T Cells in Halifax T Cells in New York T Cells in Los Angeles T Cells in Chicago T Cells in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease